By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GenomeDx Biosciences 

400 – 311 Water Street

Vancouver  British Columbia  BC V6B 1B8  Canada
Phone: 1-888-975-4540 Fax: n/a


SEARCH JOBS


Industry
Diagnostics






Company News
GenomeDx Biosciences And Color Collaborate To Further Advance Precision Medicine For Prostate Cancer Patients And Their Families 5/12/2017 8:07:04 AM
GenomeDx Biosciences's Decipher GRID Aids In Development And Validation Of Molecular Subtypes In Prostate Cancer That Predict Response To Hormone Therapy 5/11/2017 11:11:42 AM
GenomeDx Biosciences Launches Decipher Bladder Cancer Classifier Following Publication Of Study On Development, Validation Of Molecular Subtyping In Muscle-Invasive Bladder Cancer Patients 5/10/2017 6:48:50 AM
GenomeDx Biosciences Appoints Michael Rodriguez As Chief Financial Officer 5/9/2017 8:23:19 AM
GenomeDx Biosciences's Decipher Post-Op Demonstrates Positive Impact On Physician, Patient Treatment Decisions In Multicenter Prospective Study 4/25/2017 9:31:19 AM
GenomeDx Biosciences Announces Initiation By Michigan Urological Surgery Improvement Collaborative 3/2/2017 8:02:29 AM
GenomeDx Biosciences Announces Research Collaboration With Astellas (ALPMY) To Identify Genomic Drivers Of Patient Response To XTANDI (Enzalutamide) Capsules 2/1/2017 8:38:16 AM
GenomeDx Biosciences Release: Diagnostic Company's Decipher Biopsy Demonstrates Ability To Predict Metastasis After Radiation And Androgen Deprivation Therapy In Prostate Cancer Patients 1/25/2017 9:55:04 AM
GenomeDx Biosciences's Decipher GRID Aids In Development And Validation Of The First Molecular Signature To Predict Response To Radiotherapy In Prostate Cancer 10/19/2016 9:17:15 AM
GenomeDx Biosciences And Bostwick Laboratories Announce Marketing Agreement For Decipher Prostate Cancer Classifier Test 10/4/2016 6:55:42 AM
1234567
//-->